Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.

Xavier Boumaza, Baptiste Bonneau,Damien Roos-Weil,Carmela Pinnetti,Sebastian Rauer,Louisa Nitsch,Arnaud Del Bello,Ilijas Jelcic,Kurt-Wolfram Sühs,Jacques Gasnault,Yasemin Goreci,Oliver Grauer,Sharmilee Gnanapavan,Rebecca Wicklein,Nicolas Lambert, Thomas Perpoint,Martijn Beudel,David Clifford,Agnès Sommet,Irene Cortese,Guillaume Martin-Blondel

Annals of neurology（2023）

引用 14|浏览23

暂无评分

摘要

In this noncontrolled retrospective study of patients with PML who were treated with immune checkpoint inhibitors, mortality remains high. Development of inflammatory features or overt PML-IRIS was commonly observed. This study highlights that use of immune checkpoint inhibitors should be strictly personalized toward characteristics of the individual PML patient. ANN NEUROL 2023;93:257-270.

查看译文

关键词

inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要